Results 61 to 70 of about 626,377 (227)

Treatment effect of PCSK9 inhibitors.

, 2019
Treatment effect of PCSK9 inhibitors.
Alaeldin Addas (6236810), Gerhard Hindricks (52344), Michael Borger (5003072), Michael Kühl (132789), Christian Binner (6236801), Joanna Jozwiak (6236804), Boris Dinov (6236813), Julia Fischer (173836), Jochen Hahn (6236807), Jens Garbade (6236816)   +9 more
core   +1 more source

The Evolving Future of PCSK9 Inhibitors

Journal of the American College of Cardiology, 2018
Variants in proprotein convertase subtilisin/kexin type 9 (PCSK9) provide insights into mechanisms regulating low-density lipoprotein (LDL) levels. Human monoclonal antibodies that target PCSK9 lower LDL cholesterol (LDL-C) levels by 55% to 72% in different high-risk patient groups.
Robert S, Rosenson, Robert A, Hegele, Sergio, Fazio, Christopher P, Cannon   +3 more
openaire   +2 more sources

The efficacy and safety of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors combined with statins in patients with hypercholesterolemia: a network meta-analysis

Frontiers in Cardiovascular Medicine
BackgroundIn recent years, the position of PCSK9 inhibitors as adjuvant therapy to statins in guidelines has further improved. However, there remained a dearth of direct comparative studies among different PCSK9 inhibitors. Therefore, this study aimed to
Dong Liu, Jin Zhang, Xiaoyu Zhang, Fengli Jiang, Yiping Wu, Beibei Yang, Xinghuan Li, Xiongxiong Fan, Han Li, Yu Sun, Ruijie Gou, Xinyu Wang   +11 more
doaj   +1 more source

A New Strategy for Rapidly Screening Natural Inhibitors Targeting the PCSK9/LDLR Interaction In Vitro

Molecules, 2018
The interaction between proprotein convertase subtilisin/kexin type 9 (PCSK9) and the low-density lipoprotein receptor (LDLR) is a promising target for the treatment of hyperc-holesterolemia.
Li Li, Chen Shen, Ya-Xuan Huang, Ya-Nan Li, Xiu-Feng Liu, Xu-Ming Liu, Ji-Hua Liu   +6 more
doaj   +1 more source

Restores Aβ Clearance by Overcoming PCSK9–LRP1 Dysregulation and TRIB3‐Mediated Autophagy Blockade in Alzheimer's Disease

Advanced Science, EarlyView.
PCSK9 upregulation in cerebrovascular endothelial cells and microglia destabilizes the Aβ transporter LRP1, while TRIB3‐associated autophagy blockade further limits intracellular Aβ degradation. A RAP‐modified tea‐polyphenol nanoparticle co‐delivers siPCSK9 and siTRIB3 to restore LRP1‐mediated Aβ efflux and autophagy‐dependent degradation, reducing Aβ ...
Jie Miao, Jing Wang, Yankun Li, Haipei Zhang, Yanli Zhang, Qingnian Li, Bo Xiao, Wenhu Zhou, Junhong Guo   +8 more
wiley   +1 more source

Inhibitors of PCSK9 enzyme as a drug for hypercholesterolemia

, 2020
New class of drugs, fully humanized monoclonal antibodies, evolocumab and alirocumab, work as PCSK9 inhibitors. Evolocumab and alirocumab bind free plasma PCSK9 and lead to its degradation, as a result, less free PCSK9 is available in the plasma to bind ...
Nashashibi, Mary
core  

Neurocognitive effects associated with proprotein convertase subtilisin-kexin type 9 inhibitor use: a narrative review

Therapeutic Advances in Drug Safety, 2021
Neurocognitive adverse events have been observed with the widespread use of 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors or “statins,” which reduce low-density lipoprotein cholesterol (LDL-C) levels and subsequently cardiovascular risk. The United
Wei C. Yuet, Didi Ebert, Michael Jann
doaj   +1 more source

Ilexoside K Ameliorates Atherosclerosis by Suppressing CD72hi Macrophages and Blocking CXCL12–CXCR4 Axis to Inhibit Endothelial Pyroptosis

Advanced Science, EarlyView.
CD72hi macrophages drive endothelial pyroptosis and accelerate atherosclerosis through CXCL12–CXCR4‐mediated immune–vascular crosstalk. Ilexoside K suppresses this pathogenic communication by modulating CXCR4‐dependent endothelial responses, reducing inflammation and plaque progression. These findings reveal a macrophage–endothelial regulatory axis and
Xingling He, Sijing Li, Jiahui Chen, Liyu Lin, Xinyu Li, Xiaojiao Zhang, Yihui Zhang, Xingling Chen, Jinjian Guo, Zhongqi Yang, Lu Lu, Shihao Ni   +11 more
wiley   +1 more source

Aortic valve disease: Novel animal models for advancing our understanding of the underlying mechanisms

Animal Models and Experimental Medicine, EarlyView.
Due to the complex pathophysiology of aortic valve disease (AVD) and the resulting lack of effective pharmacotherapy, existing animal models are valuable research tools, but each has its own strengths and limitations. This review systematically surveys the major AVD models, compares their induction methods, pathological features, advantages and ...
Liya Hou, Xue Liu, Wangxing Hu, Xianbao Liu, Wei Zhu   +4 more
wiley   +1 more source

Monotherapy with the PCSK9 inhibitor alirocumab versus ezetimibe in patients with hypercholesterolemia:Results of a 24week, double-blind, randomized Phase 3 trial [PDF]

, 2014
Background:Efficacy and safety of alirocumab were compared with ezetimibe in hypercholesterolemic patients at moderate cardiovascular risk not receiving statins or other lipid-lowering therapy. Methods In a Phase 3, randomized, double-blind, double-dummy
Merlet, Laurence, Robinson, Jennifer G., Kastelein, John J.P., Roth, Eli M., Colhoun, Helen M., Pordy, Robert, Taskinen, Marja-Riitta, Ginsberg, Henry N., Kastelein, John J. P., Baccara-Dinet, Marie T.   +9 more
core   +1 more source